Nantkwest tries to catch the NK cell wave

Nantkwest was one of the first companies to investigate NK cells, so it could hardly have escaped the mania sweeping the sector over this class of therapeutics. Its shares surged 25% this morning on a case report that the group claims validates its recently begun Car-NK cell study in pancreatic cancer.